- Home
- GANX vs LTBR Comparison
GANX vs LTBR Comparison
Compare GANX & LTBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- LTBR
- Stock Information
- Founded
- GANX 2017
- LTBR 1992
- Country
- GANX United States
- LTBR United States
- Employees
- GANX N/A
- LTBR N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- LTBR Professional Services
- Sector
- GANX Health Care
- LTBR Consumer Discretionary
- Exchange
- GANX Nasdaq
- LTBR Nasdaq
- Market Cap
- GANX 41.9M
- LTBR 45.5M
- IPO Year
- GANX 2021
- LTBR N/A
- Fundamental
- Price
- GANX $2.28
- LTBR $5.69
- Analyst Decision
- GANX Strong Buy
- LTBR
- Analyst Count
- GANX 5
- LTBR 0
- Target Price
- GANX $7.60
- LTBR N/A
- AVG Volume (30 Days)
- GANX 264.8K
- LTBR 904.9K
- Earning Date
- GANX 11-14-2024
- LTBR 02-26-2025
- Dividend Yield
- GANX N/A
- LTBR N/A
- EPS Growth
- GANX N/A
- LTBR N/A
- EPS
- GANX N/A
- LTBR N/A
- Revenue
- GANX N/A
- LTBR N/A
- Revenue This Year
- GANX N/A
- LTBR N/A
- Revenue Next Year
- GANX N/A
- LTBR N/A
- P/E Ratio
- GANX N/A
- LTBR N/A
- Revenue Growth
- GANX N/A
- LTBR N/A
- 52 Week Low
- GANX $0.89
- LTBR $2.21
- 52 Week High
- GANX $5.33
- LTBR $14.20
- Technical
- Relative Strength Index (RSI)
- GANX 57.43
- LTBR 51.64
- Support Level
- GANX $2.06
- LTBR $5.12
- Resistance Level
- GANX $2.65
- LTBR $5.57
- Average True Range (ATR)
- GANX 0.29
- LTBR 0.68
- MACD
- GANX 0.01
- LTBR 0.05
- Stochastic Oscillator
- GANX 66.36
- LTBR 45.38
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. The company derives revenues from collaboration and licensing agreements.
About LTBR Lightbridge Corporation
Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through Nuclear Fuel Technology segment. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.